Semaglutide, Tirzepatide, Retatrutide: Three Generations of Metabolic Peptide Research
In the space of a few years, the science of weight and metabolism has moved through three distinct generations of molecule. Each one has built on the last, and each has taught researchers something new about how the body regulates appetite, blood sugar and energy. Understanding how semaglutide, tirzepatide and retatrutide differ is the clearest way to see where the field is heading.
Generation one: a single signal
Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a hormone released by the gut after eating that encourages insulin release, slows stomach emptying and signals fullness to the brain. Natural GLP-1 lasts only minutes in the bloodstream, so semaglutide was engineered with a fatty acid chain that lets it bind to albumin and last for about a week.
Its success proved that targeting gut hormones could produce substantial, sustained effects on body weight, and it turned GLP-1 from a diabetes niche into one of the most studied pathways in medicine.
Generation two: two signals in one
Tirzepatide added a second hormone to the picture. It activates both the GLP-1 receptor and the receptor for GIP, glucose-dependent insulinotropic polypeptide, another gut hormone involved in insulin release and fat storage. For years, GIP had been considered an unlikely target. Tirzepatide showed that combining it with GLP-1 in a single molecule produced larger effects in clinical trials than GLP-1 alone.
That result changed how researchers think about drug design. Instead of hitting one receptor as hard as possible, the new approach was to coordinate several of the body’s own signals at once.
Generation three: adding glucagon
Retatrutide, developed by Eli Lilly and still in Phase 3 trials, takes the idea one step further. It is a triple agonist, acting on GLP-1, GIP and glucagon receptors. Glucagon is best known for raising blood sugar, but it also increases energy expenditure and influences how the liver handles fat. In principle, combining it with the two incretin signals allows one molecule to act on both appetite and energy use.
Phase 2 data published in 2023 reported average weight reductions of around 24% over 48 weeks at the highest dose, larger than either earlier compound had shown at a similar stage. Researchers are also closely studying its effects on liver fat, where the glucagon component may be especially relevant.
How they compare in the lab
For laboratory scientists, the three compounds are not simply stronger and weaker versions of each other. They are different tools for answering different questions. Semaglutide isolates the GLP-1 pathway. Tirzepatide lets researchers study how GLP-1 and GIP interact. Retatrutide adds glucagon signalling, making it possible to explore how all three pathways combine in fat tissue, liver cells and the brain.
Comparative studies using all three can reveal which effects depend on which receptor. That kind of work underpins the next round of drug design, including compounds aimed at preserving muscle during weight loss or targeting specific organs.
The research supply side
Because tirzepatide is now a licensed medicine and retatrutide remains investigational, laboratories studying the newest compound rely on research-grade supply. Retatrutide sold for research comes as a freeze-dried powder in sealed vials, intended strictly for in vitro work.
Quality varies widely between suppliers. The standard researchers look for is independent testing: HPLC purity above 98%, identity confirmed by mass spectrometry, and a certificate of analysis tied to the batch number on the vial. UK-based Revial Labs publishes third-party results for its research-grade retatrutide on that basis.
The regulatory picture
It is important to be clear about status. Semaglutide and tirzepatide are licensed prescription medicines in the UK, available through the NHS and registered pharmacies for eligible patients. Retatrutide is not approved by the MHRA, the FDA or any other regulator. For a straightforward explanation of where retatrutide stands in the UK and why it is classed as a research compound, see this retatrutide UK guide.
Anyone interested in weight management for themselves should speak to a GP or pharmacist about the licensed options available today.
What comes next
The progression from one receptor to two to three has been remarkably fast. Researchers are already exploring combinations with amylin analogues, oral versions of these peptides and compounds designed to protect lean mass. Whether retatrutide reaches the market or not, it has already shown how far the multi-receptor approach can go.
For now, the three generations sit side by side in laboratories around the world, each helping to explain a different part of one of the most complex systems in human biology.
Compounds discussed in this article that are supplied for research are strictly for laboratory use only and are not for human or veterinary use.
